Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.

Authors: Cibeira, MT  De Larrea, CF  Navarro, A  Diaz, T  Fuster, D  Tovar, N  Rosinol, L  Monzo, M  Blade, J 
Citation: Cibeira MT, etal., Leuk Res. 2011 Sep;35(9):1178-83. doi: 10.1016/j.leukres.2011.02.009. Epub 2011 Mar 23.
Pubmed: (View Article at PubMed) PMID:21435719
DOI: Full-text: DOI:10.1016/j.leukres.2011.02.009

Single nucleotide polymorphisms (SNPs) in 12 genes involving multidrug resistance, drug metabolic pathways, DNA repair systems and cytokines were examined in 28 patients with relapsed/refractory multiple myeloma (MM) treated with single agent thalidomide and the results were correlated with response, toxicity and overall survival (OS). The response rate was higher in patients with SNPs in ERCC1 (rs735482) (p=0.006), ERCC5 (rs17655) (p=0.04) or XRCC5 (rs1051685) (p=0.013). Longer OS was associated with the SNP in ERCC1 (rs735482) (p=0.005) and XRCC5 (rs1051685) (p=0.02). Finally, polymorphism in GSTT1 (rs4630) was associated with a lower frequency of thalidomide-induced peripheral neuropathy (p=0.04).


Disease Annotations
Phenotype Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 10450871
Created: 2016-01-22
Species: All species
Last Modified: 2016-01-22
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.